A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT06679946 · tracked via the Priya Life Science USA tracker

Sponsor

Alnylam Pharmaceuticals

Phase

Phase 3

Started

2024-12-03

Last updated

2026-02-20

Condition(s) studied

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Investigational drug(s) / intervention(s)

Vutrisiran

Vutrisiran: Vutrisiran administered SC q3M

Study summary

The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients who are participating in the patisiran parent studies ALN-TTR02-011 or ALN-TTR02-014 or who have completed the 24-month OLE Period in the vutrisiran parent study ALN-TTRSC02-003 Exclusion Criteria: * Has permanently discontinued study drug administration while participating in the parent studies, ALN-TTR02-011, ALN-TTR02-014, or ALN-TTRSC02-003 * Future or current participation in another investigational device or drug study, scheduled to occur during this study * Has other medical conditions or comorbidities which, in the opinion of the Investigator, would interfere with study compliance or data interpretation

Primary outcome measure(s)

Frequency of Adverse Events (AEs) — Up to 36 Months
An AE is any untoward medical occurrence in a patient or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

Trial sites (87)

Facility	City	Region
Clinical Trial Site	Phoenix	Arizona
Clinical Trial Site	Beverly Hills	California
Clinical Trial Site	La Jolla	California
Clinical Trial Site	Stanford	California
Clinical Trial Site	Washington D.C.	District of Columbia
Clinical Trial Site	Chicago	Illinois
Clinical Trial Site	Glenview	Illinois
Clinical Trial Site	Indianapolis	Indiana
Clinical Trial Site	Kansas City	Kansas
Clinical Trial Site	Baltimore	Maryland
Clinical Trial Site	Boston	Massachusetts
Clinical Trial Site	Boston	Massachusetts
Clinical Trial Site	Rochester	Minnesota
Clinical Trial Site	St Louis	Missouri
Clinical Trial Site	Omaha	Nebraska
Clinical Trial Site	New York	New York
Clinical Trial Site	New York	New York
Clinical Trial Site	Durham	North Carolina
Clinical Trial Site	Cleveland	Ohio
Clinical Trial Site	Columbus	Ohio
Clinical Trial Site	Philadelphia	Pennsylvania
Clinical Trial Site	Nashville	Tennessee
Clinical Trial Site	Dallas	Texas
Clinical Trial Site	Salt Lake City	Utah
Clinical Trial Site	Buenos Aires	Argentina
Clinical Trial Site	Buenos Aires	Argentina
Clinical Trial Site	Buenos Aires	Argentina
Clinical Trial Site	Córdoba	Argentina
Clinical Trial Site	Rosario	Argentina
Clinical Trial Site	Rosario	Argentina
Clinical Trial Site	Rosario	Argentina
Clinical Trial Site	Vienna	Austria
Clinical Trial Site	Vienna	Austria
Clinical Trial Site	Aalst	Belgium
Clinical Trial Site	Anderlecht	Belgium
Clinical Trial Site	Dendermonde	Belgium
Clinical Trial Site	Ghent	Belgium
Clinical Trial Site	Hasselt	Belgium
Clinical Trial Site	Leuven	Belgium
Clinical Trial Site	Liège	Belgium

+ 47 more sites — see the full list on the official registry below.

On this site

📄 Amvuttra (vutrisiran) drug profile →

More Alnylam Pharmaceuticals trials in the USA

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) Recruiting

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Recruiting

A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran Recruiting

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma Recruiting

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting Recruiting

Other trials for the same condition

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Active, not recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06679946 on ClinicalTrials.gov ↗ ← All trials in the USA